Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure

M. I. Milowsky, M. Meeneghan, W. A. Wood, A. K. Green, S. B. Dusetzina, K. E. Reeder-Hayes, E. Basch, R. W. Corty
Mitoxantrone was approved for use in metastatic castrate-resistant prostate cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase III trial in 1996. To re-evaluate for possible survival benefits in a larger contemporary sample and to demonstrate analytic uses of the newly available Project Data Sphere online resource, we used data from control arms of completed clinical trials to compare survival and toxicity among patients with postdocetaxel mCRPC treated
more » ... xel mCRPC treated with mitoxantrone and prednisone.
doi:10.17615/9j28-vc86 fatcat:wixdxnpwyneehpb2cnf7jgpcaq